Pieris Pharmaceuticals In... (PIRS)
NASDAQ: PIRS
· Real-Time Price · USD
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 10:00 PM
Pieris Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | -53K | n/a | n/a | 53K | 1.3M | 19.52M | 20.05M | 1.94M | 5.85M | 5.37M | 3.7M | 10.99M | 8.44M | 4.06M | 3.29M | 15.63M |
Cost of Revenue | n/a | 721K | n/a | 751K | -30K | 4.45M | 739K | 725K | 571K | 585K | 772K | 11.95M | 840K | 588K | 18.94M | 15.8M | 16.56M |
Gross Profit | n/a | 668K | n/a | -751K | 83K | -3.15M | 18.78M | 19.33M | 1.36M | 5.26M | 4.6M | -8.25M | 10.15M | 7.86M | -14.88M | -12.52M | -929K |
Operating Income | n/a | 12.62M | -3.13M | -4.18M | -5.3M | -5.48M | -11.81M | 2.06M | -15.51M | -11.52M | -12.17M | -12.33M | -7.46M | -11M | -19.01M | -16.76M | -5.06M |
Interest Income | n/a | -610K | 169K | 201K | 240K | 455K | 549K | 490K | 357K | 351K | 241K | 132K | n/a | n/a | 4K | 3K | 3K |
Pretax Income | -8.19M | -6.07M | -2.89M | -3.59M | -4.89M | -4.58M | -10.75M | 3.98M | -13.18M | -8.1M | -9.74M | -10.34M | -5.1M | -9.53M | -16.54M | -15.5M | -4.17M |
Net Income | -8.19M | -6.07M | -2.89M | -3.59M | -4.89M | -4.58M | -10.75M | 3.98M | -12.31M | -8.08M | -8.53M | -10.34M | -2.75M | -9.16M | -16.54M | -15.5M | -4.17M |
Selling & General & Admin | 3.8M | 5.2M | 3.58M | 3.43M | 4.14M | 2.33M | 6.84M | 3.66M | 4.02M | 3.98M | 3.95M | 4.08M | 4.38M | 4.08M | 4.13M | 4.25M | 4.13M |
Research & Development | 4.07M | 6.6M | -446K | 751K | 1.25M | 4.45M | 9.6M | 14.33M | 13.42M | 13.38M | 13.59M | 11.95M | 14.07M | 15.36M | 18.94M | 15.8M | 16.56M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 15.6M | 506K | -161K | -2.03M | -3.39M | -1.47M | 676K | -2.13M | -1.09M | 678K | 464K | 884K |
Operating Expenses | 7.87M | 11.8M | 3.13M | 4.18M | 5.39M | 6.78M | 16.43M | 16.41M | 15.42M | 13.97M | 16.07M | 14.84M | 16.32M | 18.35M | 21.27M | 19.25M | 20.69M |
Interest Expense | -1.22M | -3.89M | n/a | n/a | n/a | 2.33M | n/a | n/a | n/a | n/a | n/a | n/a | 3K | 6K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 12.52M | 3.13M | 4.18M | 5.36M | 6.78M | 16.43M | 16.41M | 15.42M | 13.97M | 16.07M | 14.84M | 16.32M | 18.35M | 21.27M | 19.25M | 20.69M |
Income Tax Expense | n/a | 73.28K | n/a | n/a | n/a | -699K | n/a | n/a | -871K | -26K | -1.21M | n/a | -2.36M | -372K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 110.14K | 2.23M | 1.32M | 1.3M | 1.24M | 1.24M | 1.24M | 1.1M | 931.49K | 930.6K | 929.96K | 925.68K | 921.39K | 901.64K | 846.63K | 773.81K | 703.71K |
Shares Outstanding (Diluted) | 110.14K | 2.23M | 1.32M | 1.3M | 1.24M | 1.24M | 1.24M | 1.1M | 931.49K | 930.6K | 929.96K | 925.68K | 921.39K | 901.64K | 846.63K | 773.81K | 703.71K |
EPS (Basic) | -74.32 | 1.07 | -2.19 | -2.76 | -3.95 | -3.71 | -8.7 | 3.63 | -13.22 | -8.68 | -9.17 | -11.17 | -2.98 | -10.16 | -19.53 | -20.03 | -5.93 |
EPS (Diluted) | -74.32 | 1.07 | -2.19 | -2.76 | -3.95 | -3.71 | -8.7 | 3.63 | -13.22 | -8.68 | -9.17 | -11.17 | -2.98 | -10.16 | -19.53 | -20.03 | -5.93 |
EBITDA | n/a | -9.85M | -3.13M | -4.18M | -5.3M | -4.58M | 3.83M | 4.7M | -12.61M | -7.52M | -8.96M | -9.77M | -4.26M | -9.28M | -15.95M | -14.9M | -4.43M |
EBIT | n/a | 12.62M | -3.13M | -4.18M | -5.3M | -4.58M | 3.09M | 2.06M | -13.48M | -8.1M | -10.7M | -11.15M | -5.1M | -9.9M | -17.22M | -15.96M | -5.06M |
Depreciation & Amortization | n/a | 30K | n/a | n/a | -30K | 476K | 739K | 725K | 571K | 585K | 772K | 573K | 840K | 588K | 586K | 594K | 600K |